Correlation between Rho-kinase pathway gene expressions and development and progression of glioblastoma multiforme

Tumor Biology

Volumn 34, Issue 2, 2013, Pages 1139-1144

  Erkutlu, Ibrahim ^a   Cigiloglu, Ahmet ^a   Kalender, Mehmet Emin ^a   Alptekin, Mehmet ^a   Demiryurek, A Tuncay ^a   Suner, Ali ^a   Ozkaya, Esma ^a   Ulaslı, Mustafa ^a   Camcı, Celalettin ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

Cofilin; Glioblastoma multiforme; LIM kinase; Rho kinase

Indexed keywords

MESSENGER RNA; RHO KINASE; CFL1 PROTEIN, HUMAN; CFL2 PROTEIN, HUMAN; COFILIN 1; COFILIN 2; LIM KINASE; LIMK1 PROTEIN, HUMAN; MAPK1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN BCL 2; TUMOR MARKER;

ADULT; ARTICLE; BCL2 GENE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CFL1 GENE; CFL2 GENE; CORRELATION ANALYSIS; FEMALE; GENE ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENETIC ANALYSIS; GENETIC CORRELATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; LIMK1 GENE; MAJOR CLINICAL STUDY; MALE; MAPK1 GENE; ONCOGENE; PRIORITY JOURNAL; RNA ISOLATION; BRAIN; BRAIN TUMOR; CASE CONTROL STUDY; COMPARATIVE STUDY; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

BRAIN; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; COFILIN 1; COFILIN 2; FEMALE; GLIOBLASTOMA; HUMANS; LIM KINASES; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHO-ASSOCIATED KINASES; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84877103687     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0655-9     Document Type: Article

References (37)

1. Giese A, Westphal M. Glioma invasion in the central nervous system. Neurosurgery. 1996;39:235-50.
2. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 2007;170:1445-53.
3. Berens ME, Rutka JT, Rosenblum ML. Brain tumor epidemiology, growth, and invasion. Neurosurg Clin N Am. 1990;1:1-18.
4. Mahaley Jr MS, Mettlin C, Natarajan N, Laws Jr ER, Peace BB. National survey of patterns of care for brain-tumor patients. J Neurosurg. 1989;71:826-36.
5. Surawicz TS, McCarthy BJ, Kupelian V, Jukich PJ, Bruner JM, et al. Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990-1994. Neuro Oncol. 1999;1:14-25.
6. Lim DA, Cha S, Mayo MC, Chen MH, Keles E, et al. Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. Neuro Oncol. 2007;9:424-9.
7. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007;21:2683-710.
8. Barker II FG, Chang SM, Gutin PH, et al. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery. 1998;42:709-20.
9. Burns KL, Ueki K, Jhung SL, Koh J, Louis DN. Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas. J Neuropathol Exp Neurol. 1998;57:122-30.
10. Katoh K, Kano Y, Amano M, Onishi H, Kaibuchi K, et al. Rho-kinase-mediated contraction of isolated stress fibers. J Cell Biol. 2001;153:569-84.
11. Yan B, Chour HH, Peh BK, Lim C, Salto-Tellez M. RhoA protein expression correlates positively with degree of malignancy in astrocytomas. Neurosci Lett. 2006;407:124-6.
12. Salhia B, Rutten F, Nakada M, Beaudry C, Berens M, et al. Inhibition of Rho-kinase affects astrocytoma morphology, motility, and invasion through activation of Rac1. Cancer Res. 2005;65:8792-800.
13. Zohrabian VM, Forzani B, Chau Z, Murali R, Jhanwar-Uniyal M. Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation. Anticancer Res. 2009;29:119-23.
14. Deng L, Li G, Li R, Liu Q, He Q, et al. Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo. Cancer Biol Ther. 2010;9:875-84.
15. Zhai GG, Malhotra R, Delaney M, Latham D, Nestler U, et al. Radiation enhances the invasive potential of primary glioblastoma cells via activation of the Rho signaling pathway. J Neurooncol. 2006;76:227-37.
16. Ader I, Delmas C, Bonnet J, Rochaix P, Favre G, et al. Inhibition of Rho pathways induces radiosensitization and oxygenation in human glioblastoma xenografts. Oncogene. 2003;22:8861-9.
17. Tabu K, Ohba Y, Suzuki T, Makino Y, Kimura T, et al. Oligodendrocyte lineage transcription factor 2 inhibits the motility of a human glial tumor cell line by activating RhoA. Mol Cancer Res. 2007;5:1099-109.
18. Oellers P, Schröer U, Senner V, Paulus W, Thanos S. ROCKs are expressed in brain tumors and are required for glioma-cell migration on myelinated axons. Glia. 2009;57:499-509.
19. Nieder C, Grosu AL, Astner S, Molls M. Treatment of unresectable glioblastoma multiforme. Anticancer Res. 2005;25:4605-10.
20. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-96.
21. van Genugten JA, Leffers P, Baumert BG, Tjon-A-Fat H, Twijnstra A. Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice. J Neurooncol. 2010;96:249-57.
22. Athanassiou H, Synodinou M, Maragoudakis E, Paraskevaidis M, Verigos C, et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol. 2005;23:2372-7.
23. Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamayo R, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer. 1983;52:997-1007.
24. Maekawa M, Ishizaki T, Boku S, Watanabe N, Fujita A, et al. Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science. 1999;285:895-8.
25. Sumi T, Matsumoto K, Takai Y, Nakamura T. Cofilin phosphorylation and actin cytoskeletal dynamics regulated by rho- and Cdc42-activated LIM-kinase 2. J Cell Biol. 1999;147:1519-32.
26. Scott RW, Olson MF. LIM kinases: function, regulation and association with human disease. J Mol Med (Berl). 2007;85:555-68.
27. Gunnersen JM, Spirkoska V, Smith PE, Danks RA, Tan SS. Growth and migration markers of rat C6 glioma cells identified by serial analysis of gene expression. Glia. 2000;32:146-54.
28. Yap CT, Simpson TI, Pratt T, Price DJ, Maciver SK. The motility of glioblastoma tumour cells is modulated by intracellular cofilin expression in a concentration-dependent manner. Cell Motil Cytoskeleton. 2005;60:153-65.
29. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.
30. Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene. 2008;27:6398-406.
31. Newcomb EW, Bhalla SK, Parrish CL, Hayes RL, Cohen H, et al. bcl-2 protein expression in astrocytomas in relation to patient survival and p53 gene status. Acta Neuropatho. 1997;94:369-75.
32. Newcomb EW, Cohen H, Lee SR, Bhalla SK, Bloom J, et al. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol. 1998;8:655-67.
33. Rieger L, Weller M, Bornemann A, Schabet M, Dichgans J, et al. BCL-2 family protein expression in human malignant glioma: a clinical-pathological correlative study. J Neurol Sci. 1998;155:68-75.
34. Reddy KB, Nabha SM, Atanaskova N. Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev. 2003;22:395-403.
35. Mandell JW, Hussaini IM, Zecevic M, Weber MJ, VandenBerg SR. In situ visualization of intratumor growth factor signaling: immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms. Am J Pathol. 1998;153:1411-23.
36. Mawrin C, Diete S, Treuheit T, Kropf S, Vorwerk CK, et al. Prognostic relevance of MAPK expression in glioblastoma multiforme. Int J Oncol. 2003;23:641-8.
37. Cuevas P, Díaz-González D, García-Martín- Córdova C, Sánchez I, Lozano RM, et al. Dobesilate diminishes activation of the mitogen-activated protein kinase ERK1/2 in glioma cells. J Cell Mol Med. 2006;10:225-30.